CA-SERVICENOW,-INC.
ServiceNow (NYSE:NOW), the leading digital workflow company that makes work, work better for people, today announced that Paul Smith has joined the company as Senior Vice President and General Manager, EMEA, effective July 7, 2020. Smith joins the company from Salesforce, where he held a number of pan EMEA roles and most recently served as Executive Vice President and UK General Manager.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200707005309/en/
Smith brings to ServiceNow 17 years’ experience in leadership and senior management roles in the technology industry, with a track record in leading sales, go-to-market operations and developing new markets to drive triple digit growth.
“ServiceNow is leading the workflow revolution as companies worldwide transform themselves into modern digital enterprises,” said ServiceNow CEO Bill McDermott. “The best leaders and top talent want to work for companies like ServiceNow, where they can create the future. We are thrilled to have Paul Smith join our team, serve our customers and lead our EMEA region to new heights on our journey to becoming the defining enterprise software company of the 21st century.”
Smith will lead a region that includes many of the company’s most important markets and growth opportunities. ServiceNow’s EMEA revenues grew 32 percent in 2019 over the prior year; EMEA achieved an approximately $1 billion revenue run-rate as of Q1 2020.
“ServiceNow is the workflow leader and one of the most exciting and innovative growth companies in the world,” Smith said. “The pristine nature of the single Now Platform gives ServiceNow that rare combination of scale with agility. It’s this exact blend that customers are demanding of their critical partners as they wrestle with digitally transforming their businesses to navigate the change that is yet to come.”
Smith continued: “There are moments in your life when career defining opportunities present themselves; ServiceNow is one of those for me. The talented workforce and commitment to customer and partner success sets it apart from other global brands. I’m thrilled to join and privileged to have the opportunity to lead the EMEA business during the next phase of growth.”
Smith succeeds Phillip van der Wilt who served in this role from January 2016 to July 2020. During this time, and under van der Wilt’s leadership, the EMEA business grew rapidly and established ServiceNow’s strong foothold across EMEA.
“Many thanks to Philip for his leadership in growing our EMEA region over the past four years and establishing ServiceNow as a strategic partner to many of the world’s leading companies,” said Kevin Haverty, ServiceNow’s Executive Vice President of Worldwide Sales. “With Paul on our team, we are set to continue our momentum and drive the next phase of growth. Paul’s strong experience and exceptional track record across the region will help ensure ServiceNow accelerates our leadership as the partner of choice for C-suite leaders driving digital transformation.”
Smith began his career with Procter and Gamble but soon followed a passion for the technology industry that took him to Microsoft and leadership of a number of innovative start-up businesses. He joined Salesforce in 2012 to lead their EMEA Marketing Cloud business, before going on to lead EMEA Cloud Sales until his appointment as EVP and GM UK&I in February 2019.
About ServiceNow
ServiceNow (NYSE: NOW) is making the world of work, work better for people. Our cloud-based platform and solutions deliver digital workflows that create great experiences and unlock productivity for employees and the enterprise. For more information, visit: www.servicenow.com .
© 2020 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005309/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom